Ultimately, the choice between Melanotan 1 vs Melanotan 2 depends on the users specific goals, desired benefits, and tolerance for potential side effects
The Obesity Market Is Still Growing, but the Debate Has Changed The GLP-1 obesity market remains one of the most attractive growth pools in global pharma, but investor debate has shifted
By August 2025, prescribing rates had risen to 335 prescriptions per 100,000 encounters
An updated meta-analysis: Risk conferred by glutathione S-transferases (GSTM1 and GSTT1) polymorphisms to age-related cataract
GLP-1 Agonists in Type 1 DiabetesIndications and Use
One of the most common and devastating severe manifestations of SLE is lupus nephritis (LN), which affects an estimated 40-70% of lupus patients